Additionally, cabozantinib is also known as an AXL inhibitor, and biomarkers may be identified in an ongoing clinical trial in NSCLC patients with AXL overexpression, amplication, or mutation (NCT01639508). This evidence concerns the gene AXL and non-small cell lung carcinoma.